Board-certified Pain Specialists
At PA Pain & Spine Institute, we now offer Qutenza treatment for post-herpetic neuralgia and neuropathic pain. Because capsaicin patch therapy acts directly at the skin's nerve fibers rather than through the bloodstream, it avoids many of the side effects that come with systemic drugs.
Because small fiber neuropathy is caused by damage to the smallest sensory nerve fibers, almost any condition that affects the peripheral nervous system can be responsible. In many patients, however, one or more of the following underlying causes can be identified through targeted follow-up testing after the biopsy confirms the diagnosis:
✅ Diabetes and prediabetes
✅ Autoimmune disorders
✅ Thyroid disease
✅ Vitamin B12 deficiency
✅ Celiac disease and gluten sensitivity
✅ Genetic mutations
✅ Idiopathic SFN
Qutenza treatment may treat post-herpetic neuralgia, commonly abbreviated as PHN, develops as a complication of shingles. Shingles itself results from the reactivation of the varicella-zoster virus. This is the same virus responsible for chickenpox. After a person recovers from chickenpox, the virus remains dormant in the nerve tissue. In some individuals, the virus later reactivates and travels along the nerve pathways to the skin.
The rash from shingles typically resolves within a few weeks. However, for a significant portion of patients, the nerve damage that occurred during the infection persists long afterward. The result is PHN: a burning, stabbing, or electric pain that affects the area where the rash appeared. In many cases, even light touch to the skin becomes unbearable.
The active ingredient in Qutenza is capsaicin at a concentration of eight percent. Capsaicin is a naturally occurring compound derived from chili peppers. At high concentrations, it acts on a specific receptor in the skin called the transient receptor potential vanilloid 1, or TRPV1, receptor. This receptor sits on the surface of pain-sensing nerve fibers in the skin and plays a key role in transmitting pain signals.
When capsaicin at high concentration activates the TRPV1 receptor repeatedly, it triggers a process called defunctionalization. In plain terms, the pain-sensing nerve fibers in the treated area temporarily lose their ability to send pain signals. This is not nerve destruction. Rather, it is a reversible reduction in nerve fiber activity.
Over-the-counter capsaicin creams typically contain concentrations between 0.025 and 0.25 percent. These require daily application and produce limited results. Qutenza treatment contains eight percent capsaicin and is applied once under clinical supervision. A single application can provide relief lasting up to three months. Because a healthcare professional administers it in a controlled setting, there is no risk of accidental exposure or improper application.

Step 1: Anesthetic Pre-Treatment A topical anesthetic is applied to the treatment area approximately one hour before the patch is placed. This numbs the skin and reduces the initial warmth or tingling from the capsaicin. Our team monitors your comfort throughout.

The Qutenza patch is applied to the painful area and left in place for 60 minutes. Our clinical team supervises the full procedure. The patch is sized to fit the area being treated, using up to four patches per session as needed.

After the patch is removed, a cleansing gel clears any residual capsaicin from the skin. Most patients leave the office the same day with no downtime. Pain relief typically builds over the following one to two weeks.
Most patients experience a mild warming or burning sensation during the Qutenza treatment. This is expected and indicates the treatment is working. Because a topical anesthetic is applied beforehand, the sensation is generally manageable. Our clinical team stays with patients throughout the appointment to monitor comfort.
A single treatment typically provides pain relief for up to three months. Some patients experience benefit for longer. Because the effect is reversible, treatment can be repeated every three months if pain returns. Each subsequent treatment follows the same in-office protocol.
No. The entire procedure takes place in our office in Chalfont or Quakertown. Patients do not need a hospital visit, an outside referral, or general anesthesia. Most patients return to normal activity the same day.
Yes. Qutenza is FDA-approved for the management of neuropathic pain associated with post-herpetic neuralgia. It has been studied in multiple large randomized controlled trials and is supported by a significant body of peer-reviewed clinical evidence.
Research insight: A retrospective study using skin biopsy with IENFD analysis detected abnormalities in 88.1% of patients with symptoms suggestive of sensory neuropathy but normal nerve conduction studies, compared with only 10% of healthy controls. Skin biopsy was more often abnormal than either clinical examination or quantitative sensory testing in this population. [Larner et al., PubMed 20065802]
Patients who come to our practice benefit from:
If you have been living with post-herpetic neuralgia, shingles-related nerve pain, or another form of localized neuropathic pain, Qutenza may provide the targeted relief you have not found elsewhere. At PA Pain & Spine Institute, our specialists in Chalfont and Quakertown are ready to evaluate your situation and determine whether this treatment is right for you. Schedule a consultation to:
Standard pain medications provide only partial relief for many PHN patients. Anticonvulsants like gabapentin and pregabalin, as well as tricyclic antidepressants, are commonly prescribed. While these medications help some patients, they carry systemic side effects such as drowsiness, cognitive fog, and weight changes. Furthermore, not all patients see meaningful pain reduction, even at therapeutic doses.
This is precisely why a localized, non-systemic option like Qutenza represents a meaningful advance. Rather than treating the entire nervous system, Qutenza works directly at the site of nerve damage in the skin. Consequently, patients who have not responded to oral therapies often find this approach more effective.
Qutenza is not limited to PHN. It has also shown benefit for other forms of peripheral neuropathic pain. This includes painful diabetic peripheral neuropathy and other localized nerve pain conditions affecting the skin. Patients in Chalfont and the surrounding Bucks County area who experience ongoing nerve pain in a defined body region may be good candidates for this therapy.
The information on this page is for general educational purposes only and does not constitute medical advice. Treatment recommendations are based on individual clinical evaluation. Individual results may vary, and no specific outcomes are guaranteed. This content does not create a provider-patient relationship.
